[1] Lawn, S. D. & Zumla, A. I. Tuberculosis. Lancet 378, 57-72, doi:10.1016/S0140-6736(10)62173-3 (2011).
[2］World Health Organization. Global tubeculosis report 2019. Geneva, World Health Organization, 2020.
[3］Gao, L. et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis 15, 310-319, doi:10.1016/S1473-3099(14)71085-0 (2015).
[4］Munoz, L., Stagg, H. R. & Abubakar, I. Diagnosis and Management of Latent Tuberculosis Infection. Cold Spring Harb Perspect Med, doi:10.1101/cshperspect.a017830 (2015).
[5］Mack, U. et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 33, 956-973, doi:10.1183/09031936.00120908 (2009).
[6］Huebner, R. E., Schein, M. F. & Bass, J. B., Jr. The tuberculin skin test. Clin Infect Dis 17, 968-975 (1993).
[7］Menzies, D., Pai, M. & Comstock, G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146, 340-354 (2007).
[8］Pai, M. & Menzies, D. The new IGRA and the old TST: making good use of disagreement. Am J Respir Crit Care Med 175, 529-531, doi:10.1164/rccm.200701-024ED (2007).
[9］Cavusoglu, C., Yasar-Duman, M., Sezai Tasbakan, M., Isikgoz-Tasbakan, M. & Nurullah Orman, M. Evaluation of the performance of QuantiFERON(R)-TB Gold plus test in active tuberculosis patients. J Clin Tuberc Other Mycobact Dis 23, 100223, doi:10.1016/j.jctube.2021.100223 (2021).
[10］Diel, R., Loddenkemper, R. & Nienhaus, A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 137, 952-968, doi:10.1378/chest.09-2350 (2010).
[11］Sauzullo, I., Vullo, V. & Mastroianni, C. M. Detecting latent tuberculosis in compromised patients. Current opinion in infectious diseases 28, 275-282, doi:10.1097/ QCO.0000000000000158 (2015).
[12］Rangaka, M. X. et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12, 45-55, doi:10.1016/S1473-3099(11)70210-9 (2012).
[13］Getahun, H., Matteelli, A., Chaisson, R. E. & Raviglione, M. Latent Mycobacterium tuberculosis infection. The New England journal of medicine 372, 2127-2135, doi:10.1056/ NEJMra1405427 (2015).
[14］Lindestam Arlehamn, C. S. et al. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog 9, e1003130, doi:10.1371/journal. ppat.1003130 (2013).
[15］Chegou, N. N. et al. Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect Dis 12, 10, doi:10.1186/1471-2334-12-10 (2012).
[16］Meier, N. R., Jacobsen, M., Ottenhoff, T. H. M. & Ritz, N. A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis. Front Immunol 9,2476, doi:10.3389/fimmu.2018.02476 (2018).
[17］Jeong, Y. H. et al. Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen- induced IP-10 production. J Clin Microbiol 53, 504-510, doi:10.1128/JCM.02758-14 (2015).
[18］Kunnath-Velayudhan, S. & Gennaro, M. L. Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery. Clin Microbiol Rev 24, 792-805, doi:10.1128/ CMR.00014-11 (2011).
[19］Zhou, F., Xu, X., Wu, S., Cui, X. & Pan, W. ORFeome-based identification of biomarkers for serodiagnosis of Mycobacterium tuberculosis latent infection. BMC Infect Dis 17, 793, doi:10.1186/s12879-017-2910-y (2017).
